This Article Full Text (PDF) All Versions of this Article: 0885066608320840v1 23/5/321    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ryan, A. Articles by Tobias, J. D. Search for Related Content PubMed PubMed Citation Articles by Ryan, A. Articles by Tobias, J. D. Social Bookmarking                   What's this?

Preliminary Experience With Nesiritide in Pediatric Patients Less Than 12 Months of Age

School of Medicine, University of Missouri, Columbia

David A. Rosen, MD

Departments of Anesthesiology and Pediatrics, University of West Virginia, Morgantown

Joseph D. Tobias, MD

Departments of Anesthesiology and Pediatrics, University of Missouri, Columbia, tobiasj{at}health.missouri.edu

The natriuretic peptide system plays an active role in the regulation of fluid balance and systemic vascular resistance. Advances in recombinant technology have provided the opportunity for the exogenous administration of a recombinant form of B-type natriuretic peptide (nesiritide). To date, reports of its use in the pediatric population are limited, with limited information regarding its use in patients less than 12 months of age. We retrospectively reviewed our experience with nesiritide in infants less than 12 months of age to determine its efficacy and adverse effect profile. The study cohort included 22 patients, ranging in age from 4 days to 12 months. The starting dose of the nesiritide infusion ranged from 0.01 to 0.05 µg/kg/min (0.015 ± 0.01µg/ kg/min) and was administered for a total of 3 to 264 hours (85.2 ± 75.0 hours). Nesiritide resulted in a significant increase in urine output even in the face of decreased fluid intake. Mean urine output increased from 3.1 ± 2.5 mL/kg/h before nesiritide to 5.7 ± 4.5 mL/kg/h (P = .03) during the initial 24 hours after starting the infusion. Fluid intake before and after the infusion were 126 ± 60 mL/kg/d and 108 ± 56 mL/kg/d, respectively. There were no statistically or clinically significant changes in hemodynamic parameters (heart rate, blood pressure, and central venous pressure) during the nesiritide infusion. No change in electrolytes, blood urea nitrogen, and creatinine were noted. No adverse effects of the nesiritide infusion were noted. No infusion was stopped due to adverse effects. These data suggest that nesiritide is a safe method of improving urine output in pediatrics patients less than 12 months of age and that the adverse effect profile does not appear to be different than that reported in older children.

Key Words: nesiritide • natriuretic peptide • congestive heart failure • congenital heart disease

This version was published on September 1, 2008

Journal of Intensive Care Medicine, Vol. 23, No. 5, 321-328 (2008)
DOI: 10.1177/0885066608320840


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?